Malignant tumors continue to threaten people's lives, and the incidence and mortality of lung cancer are particularly high. Due to different ethnic and cultural backgrounds, China and the United States differ in the clinical treatment of lung cancer and related basic research. The discrepancies are mostly visible in the prevention of cancer, the approval of anticancer drugs, availability of medical insurance, structure of medical education, availability of research funds, and many other aspects By understanding these differences, China and the United States, as well as other nations, can learn from each other and make progress together, which will help to improve the outcomes of cancer therapy.
Keywords: Difference; clinical practice; lung cancer; medical insurance.
2020 Journal of Thoracic Disease. All rights reserved.